70 Participants Needed

Randomized, Double-blind, Placebo-controlled Trial Investigating the Role of a Personal Care Product on Vaginal Health

DG
Overseen ByDirk Gevers
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Seed Health

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new personal care product, VM-02, on healthy women to improve vaginal health. The product contains beneficial bacteria and compounds to balance vaginal bacteria and reduce discomfort. Researchers will observe its effects over a few months.

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, you must agree not to use certain intra-vaginal products during the study.

What safety data exists for the treatment known as VM-02 or VM-02 Placebo?

The OptiMARK clinical development program provides safety data, but it does not specifically mention VM-02 or VM-02 Placebo. General safety data from phase-I studies involving healthy volunteers show that adverse events can occur with various treatments, but specific information about VM-02 is not available.12345

What data supports the effectiveness of the drug VM-02?

The research mentions methotrexate and epirubicin, which are components of the VEM treatment used in breast cancer, showing effectiveness in downstaging tumors to allow surgery. This suggests that these components might contribute to the effectiveness of VM-02.678910

Are You a Good Fit for This Trial?

Inclusion Criteria

Reproductive age women aged ≥ 18.
History of regular menses every 21-35 days for six months prior to the study.
Agreement not to use specified intra-vaginal products during the study product use.
See 3 more

Exclusion Criteria

Pregnancy or planned pregnancy in the next 6 months.
Two or more amenorrheic months in the past 6 months.
Lives in the state of New York.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the personal care product or placebo according to their assigned arm. The treatment involves vaginal suppository capsules, tablets, or oral capsules administered over two menstrual cycles.

8 weeks
8 virtual check-ins

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments of vaginal microbiome changes and user experience.

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • VM-02
  • VM-02 Placebo
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Placebo Group
Group I: Vaginal Suppository Tablet ActiveExperimental Treatment1 Intervention
In the VM-02 Vaginal Suppository Tablet Active Arm, participants will take a test vaginal suppository tablet as directed.
Group II: Vaginal Suppository Capsule ActiveExperimental Treatment1 Intervention
In the VM-02 Vaginal Suppository Capsule Active Arm, participants will take a test vaginal suppository capsule as directed.
Group III: Oral Capsule ActiveExperimental Treatment1 Intervention
In the VM-02 Oral Capsule Active Arm, participants will take a test oral capsule as directed.
Group IV: Commercial Oral Vaginal Probiotic CompetitorExperimental Treatment1 Intervention
In the Commercial Over-The-Counter (OTC) Oral Probiotic Competitor Arm, participants will take an over-the-counter competitor product as directed.
Group V: Vaginal Suppository CapsulePlacebo Group1 Intervention
In the VM-02 Vaginal Suppository Capsule Placebo Arm, participants will take the test vaginal suppository capsule placebo as directed.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Seed Health

Lead Sponsor

Trials
5
Recruited
480+

Published Research Related to This Trial

Adjuvant chemotherapy significantly improves overall survival, disease-specific survival, and disease-free survival in high-risk Stage II colorectal cancer patients, with a hazard ratio of 0.61 for overall survival, based on a meta-analysis of 29 studies involving 183,749 participants.
The benefits of chemotherapy were consistent across various subgroups, including patients with multiple high-risk features and those with colon cancer, indicating that it can be an important treatment option for improving patient outcomes.
Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis.Simillis, C., Singh, HKSI., Afxentiou, T., et al.[2021]
The safety of marketed drugs is a significant concern, as some commonly prescribed medications can lead to serious or life-threatening side effects in patients.
The ChEMBL resource will provide a curated drug safety data set, including toxicity classifications and black box warnings, which will be freely available and regularly updated to aid in drug safety research and discovery.
Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs.Hunter, FMI., Bento, AP., Bosc, N., et al.[2023]
In a comprehensive review of 54 phase-I studies involving 1015 healthy volunteers over 10 years, the overall incidence of adverse events was found to be 12.8%, with a higher rate for active drugs (13.7%) compared to placebo (7.9%).
Most adverse events were minor, with only 3% classified as severe, and no deaths or life-threatening events reported, highlighting that while adverse events are common in phase-I trials, they are typically not serious.
Adverse events in phase-I studies: a report in 1015 healthy volunteers.Sibille, M., Deigat, N., Janin, A., et al.[2019]

Citations

Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990-1999. [2007]
High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin. [2019]
Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis. [2021]
Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer. [2019]
Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer. [2022]
Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs. [2023]
Adverse events in phase-I studies: a report in 1015 healthy volunteers. [2019]
The OptiMARK clinical development program: summary of safety data. [2019]
The contribution of different information sources to identify adverse effects of a medical device: a case study using a systematic review of spinal fusion. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security